The Partnership to Advance Cardiovascular Health works to advance public policies and practices that result in accelerated innovation and improved cardiovascular health for heart patients around the world

PACH Releases New National Survey of Attitudes Toward Cardiovascular Treatment & Access

Click the images below to read the results.


Jeff’s Story
May 2019


Watch PCSK9 Inhibitors: Access Barriers Affect Real People
April 2017

Watch: Accessing Breakthrough Cholesterol Treatment
December 2016



PACH is a 501(c)4 non-profit advocacy organization of diverse stakeholders, including patients, patient advocates, physicians, and scientists. Its goal is to facilitate better cardiovascular health through public policies that:

        • Encourage the advancement of cardiovascular science and innovation

        • Support the education of patients, health care providers, and other stakeholders

        • Facilitate the development of improved means of preventing and treating cardiovascular disease

        • Ensure access to appropriate prevention and treatment options for all people  

To learn more, connect with PACH via email today. 



Heart health complications challenge millions of people worldwide each year. An estimated 102 million Americans have high cholesterol, with more than 35 million of these at high risk for heart disease. Globally, 17.5 million people die of cardiovascular disease annually.

In recent years, innovative advanced medical therapies and medical devices have emerged to offer new treatment options for patients – medications that better control symptoms or reduce side effects that complicate treatment. But health plan coverage has been slow to accommodate breakthrough treatments. Insurers instead have clung to older, less expensive therapies, using restrictive policy design to limit patient access.

Budget-focused policies that assume a one-size-fits-all approach to managing high cholesterol can put patient health at risk. They can also allow cost-cutting tactics to trump physician insight. For patients to benefit from breakthrough treatments for cardiovascular conditions, health policy must support access and decisions about clinical care must continue to take shape within the physician-patient relationship.